Faith Davies, MD, shares insights from the IMS 2024 session on high-risk disease, highlighting the debut of a unified high-risk definition. This new framework incorporates 17p deletions, mutations, 1q/1p abnormalities, and translocations paired with specific genetic markers, as well as beta-2 microglobulin levels above 5.5. Davies emphasizes the significance of adopting next-generation sequencing for improved accuracy and cost-efficiency compared to traditional FISH testing. The updated criteria aim to standardize clinical trials, inform regulatory discussions, and optimize treatment strategies for high-risk multiple myeloma patients, marking a pivotal step forward in patient care and research.